The Committee for Medicinal Products for Human Use (CHMP) communicates the European Medicines Agency’s (EMA) opinions on new drugs being introduced into the European union. Interestingly CHMP controls marketing for new drugs in Europe. They scientifically assess new drugs to be marketed for quality, safety and efficacy according to law. Most medicines have a risk/benefit balance relative to the patient’s well being. CHMP makes certain the balance is in favor of the patient – that the benefits are greater than the risks. CHMP also monitors drugs after they are introduced. If there is subsequent evidence that drugs are harming patients, CHMP has the power to remove them from the market.
October 22, 2012 – CHMP did not recommend the weight loss drug Qsymia (marketed as Qsiva in Europe) in the report from their October 15 – 18 meeting. Qsymia was rejected because of potential cardiovascular and central nervous system effects from long-term use.
So what does CHMP know that the US Food and Drug Administration (FDA) doesn’t? Qsymia was approved by the FDA in July 2012. CHMP not recommending Qsymia makes the the drug’s worrisome side effects even more scary. Who wants to take a drug that is deemed unacceptably dangerous by any world authority?
Children with high BPA levels are 200% more likely to be Obese
Now that’s a scary statistic. How could that be? Bisphenol A (BPA) is a colorless solid that is soluble (dissolvable) in organic solvents but not so soluble in water. It’s used in consumer products and food containers such as water bottles, soft drink and juice bottles – food packaging and canned food. Canada has declared BPA to be toxic. The European Union and Canada have banned it in the manufacture of baby bottles. The problem is that BPA may look like estrogen to the human body and because of that the human body assumes that it is something it should absorb. Compounds that look like estrogen are called xenoestrogens.
Studies show that BPA very possibly can cause neurological problems for babies in the womb. There is research that shows BPA at the normal concentrations in humans can cause changes in brain structure and function when tested on laboratory animals. Studies have also shown changes in body size and chemistry from typical human exposure levels. Typical human concentrations may also result in heart disease, diabetes – abnormalities in mammary glands (possibly breast cancer), uterus, thyroid gland, testicles, prostate (including prostate cancer) and erectile dysfunction. The list of bad effects went on and on, well beyond the scope of this writing. Again, many of these results are from tests done on animals (but more and more tests are being done on humans). This is very sobering information given almost everything is and has been (for many years) packed in plastics.
BPA exposure can result in childhood obesity? That’s not hard to believe after considering the list of ailments above. New research has shown that children with high BPA levels double their chances of becoming obese over those with lower levels. This is new information at the time of this writing so researches are quick to qualify that there may be other factors at play. This is also the first research linking a chemical as a cause for childhood obesity. It’s interesting to note that higher BPA levels only cause increased obesity in Caucasian children.
STOBBE, MIKE . “Study suggests tie between BPA and child obesity.” Yahoo News. Associated Press, 18 2012. Web. 30 Oct 2012.
“Bisphenol A.” Wikipedia. Wikipedia. Web. 30 Oct 2012.